Karyopharm Therapeutics (KPTI) Reports In-Line Q3 EPS

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.65), in-line with the analyst estimate of ($0.65). Revenue for the quarter came in at $0 , versus $30 thousand reported last year.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Stitch Fix (SFIX) Tops Q3 EPS by 4c, Offers Guidance
• Oxford Industries (OXM) Tops Q1 EPS by 12c; Offers Outlook